On October 24th, the listed company Jincheng Pharm (SZ300233) released its financial report for the third quarter of 2023. The company's operating income for the third quarter reached 863 million yuan, representing a year-on-year increase of 16.77%. However, its net profit declined by 21.95% to 30.77 million yuan, and the non-GAAP net profit also dropped by 21.17% to 26.72 million yuan.
According to a report, Jincheng Pharm achieved a total operating revenue of 2.569 billion yuan in the first three quarters of 2023, representing a year-on-year decrease of 0.87%. The net profit reached 132 million yuan, experiencing a significant decline of 48.73% compared to the same period last year. The adjusted net profit, excluding non-recurring items, stood at 119 million yuan, reflecting a 52.81% year-on-year decrease. The basic earnings per share amounted to 0.34 yuan.
According to the report, Jincheng Pharm Chemical Co., Ltd., a wholly-owned subsidiary of the company, received a "Tobacco Monopoly Production Enterprise License" (e-cigarette nicotine production) issued by the National Tobacco Monopoly Administration in July 2023.
It has been stated that the newly acquired "Tobacco Monopoly Production Enterprise License" has made changes to the approved production scale, scope of permission, and validity period of the original certificate. The company is now permitted to engage in domestic and export business of e-cigarette nicotine in compliance with the law. The production scale will not exceed the data approved by the State Tobacco Monopoly Bureau, and the validity period has been extended until June 30, 2025.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
